{"id":745083,"date":"2015-11-03T06:58:00","date_gmt":"2015-11-03T06:58:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/"},"modified":"2025-11-07T01:24:50","modified_gmt":"2025-11-07T06:24:50","slug":"gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/","title":{"rendered":"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment"},"content":{"rendered":"<ul>\n<li>         Phase I first-in-human study to evaluate GSK\u2019s OX40 agonist          GSK3174998 as monotherapy and in combination with Merck\u2019s          anti-PD-1 therapy, KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab)       <\/li>\n<\/ul>\n<p class=\"bwalignc\">\n      GSK and Merck, known as MSD outside the US and Canada, today announced<br \/>\n      the initiation of a phase I clinical trial designed to evaluate GSK\u2019s<br \/>\n      investigational immunotherapy GSK3174998 as monotherapy and in<br \/>\n      combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab)<br \/>\n      in patients with locally advanced, recurrent or metastatic solid<br \/>\n      tumour(s) that have progressed after standard treatment.\n    <\/p>\n<p>\n      GSK3174998 is a humanised IgG1 anti-OX40 monoclonal antibody that was<br \/>\n      identified through a collaboration with MD Anderson Cancer Center. OX40<br \/>\n      is a tumour necrosis factor receptor expressed on the surface of<br \/>\n      activated CD4+ and CD8+ T cells. OX40 agonism results in stimulation of<br \/>\n      both immune effector and memory functions, while also attenuating the<br \/>\n      immunosuppressive regulatory T cells that are sometimes found in<br \/>\n      tumours. GSK3174998 is one of a number of early stage assets in GSK\u2019s<br \/>\n      oncology pipeline focused on fighting the fundamental drivers of cancer.<br \/>\n      KEYTRUDA is a humanised monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumour<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, and may affect both tumour cells and healthy cells.\n    <\/p>\n<p>\n      Axel Hoos, Vice President Oncology R&amp;D at GSK, said: \u201cThere have been<br \/>\n      meaningful advances in survival across several cancers recently, mostly<br \/>\n      based on single agent checkpoint modulatory drugs. The combination study<br \/>\n      of KEYTRUDA with GSK\u2019s OX40 agonist will seek to build on that progress<br \/>\n      with the aim of contributing further improvements for patients. We think<br \/>\n      combining these two agents that use different aspects of the immune<br \/>\n      system may be an important step toward achieving this goal.\u201d\n    <\/p>\n<p>\n      \u201cThe initiation of this phase I trial with GSK is an important step in<br \/>\n      identifying synergistic treatment combinations that can potentially<br \/>\n      enhance the activity we are seeing with KEYTRUDA as a monotherapy,\u201d said<br \/>\n      Dr. Eric Rubin, vice president and therapeutic area head, oncology early<br \/>\n      stage development, Merck Research Laboratories. \u201cWe are looking forward<br \/>\n      to this trial progressing and to sharing the findings on the potential<br \/>\n      of the combination of KEYTRUDA and GSK\u2019s GSK3174998 in bringing forward<br \/>\n      improved outcomes for patients with advanced cancer.\u201d\n    <\/p>\n<p>\n      More information on the clinical trial can be found by searching for<br \/>\n      NCT02528357 on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=5c0fcd07f855014a734c6ef3d446d855\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with metastatic non-small cell lung<br \/>\n      cancer (NSCLC) whose tumors express PD-L1 as determined by an<br \/>\n      FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is<br \/>\n      also indicated at the same dosing for the treatment of patients with<br \/>\n      unresectable or metastatic melanoma and disease progression following<br \/>\n      ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. These<br \/>\n      indications are approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for these indications may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b> <b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Pneumonitis, including fatal cases, occurred in patients receiving<br \/>\n      KEYTRUDA. Pneumonitis occurred in 12 (2.9%) of 411 melanoma patients,<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively, receiving KEYTRUDA. Pneumonitis occurred in 19 (3.5%) of<br \/>\n      550 patients with NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%),<br \/>\n      or 5 (0.2%) pneumonitis in patients, receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients with melanoma, including Grade 2 or 3 cases in 1 (0.2%) and 2<br \/>\n      (0.5%) patients, respectively, receiving KEYTRUDA. Colitis occurred in 4<br \/>\n      (0.7 %) of 550 patients with NSCLC, including Grade 2 (0.2%) or 3 (0.4%)<br \/>\n      colitis in patients receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis occurred in patients receiving KEYTRUDA. Hepatitis (including<br \/>\n      autoimmune hepatitis) occurred in 2 (0.5%) of 411 patients with<br \/>\n      melanoma, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients with melanoma,<br \/>\n      including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each)<br \/>\n      patient, receiving KEYTRUDA. Hypophysitis occurred in 1 (0.2 %) of 550<br \/>\n      patients with NSCLC, which was Grade 3 in severity. Monitor patients for<br \/>\n      signs and symptoms of hypophysitis (including hypopituitarism and<br \/>\n      adrenal insufficiency). Administer corticosteroids and hormone<br \/>\n      replacement as indicated. Withhold KEYTRUDA for Grade 2 and withhold or<br \/>\n      discontinue for Grade 3 or Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients with melanoma,<br \/>\n      including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients,<br \/>\n      respectively, receiving KEYTRUDA. Hypothyroidism occurred in 34 (8.3%)<br \/>\n      of 411 patients with melanoma, including a Grade 3 case in 1 (0.2%)<br \/>\n      patient, receiving KEYTRUDA. Hyperthyroidism occurred in 10 (1.8%) of<br \/>\n      550 patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%).<br \/>\n      Hypothyroidism occurred in 38 (6.9%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (5.5%) or 3 (0.2%). Thyroid disorders can occur at any<br \/>\n      time during treatment. Monitor patients for changes in thyroid function<br \/>\n      (at the start of treatment, periodically during treatment, and as<br \/>\n      indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or Grade 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia or<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA and administer anti-hyperglycemics in<br \/>\n      patients with severe hyperglycemia.\n    <\/p>\n<p>\n      Nephritis occurred in patients receiving KEYTRUDA. Nephritis occurred in<br \/>\n      3 (0.7%) patients with melanoma, consisting of one case of Grade 2<br \/>\n      autoimmune nephritis (0.2%) and two cases of interstitial nephritis with<br \/>\n      renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or<br \/>\n      less following steroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      severe or Grade 3 immune-mediated adverse reaction that recurs and for<br \/>\n      any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Across clinical studies with KEYTRUDA, the following clinically<br \/>\n      significant, immune-mediated adverse reactions have occurred: bullous<br \/>\n      pemphigoid and Guillain-Barr\u00e9 syndrome. The following clinically<br \/>\n      significant, immune-mediated adverse reactions occurred in less than 1%<br \/>\n      of patients with melanoma treated with KEYTRUDA: exfoliative dermatitis,<br \/>\n      uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, and<br \/>\n      partial seizures arising in a patient with inflammatory foci in brain<br \/>\n      parenchyma. The following clinically significant, immune-mediated<br \/>\n      adverse reactions occurred in less than 1% of 550 patients with NSCLC<br \/>\n      treated with KEYTRUDA: rash, vasculitis, hemolytic anemia, serum<br \/>\n      sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      Among the 411 patients with metastatic melanoma, KEYTRUDA was<br \/>\n      discontinued for adverse reactions in 9% of 411 patients. Adverse<br \/>\n      reactions, reported in at least two patients, that led to<br \/>\n      discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients. The most frequent<br \/>\n      serious adverse reactions, reported in 2% or more of patients, were<br \/>\n      renal failure, dyspnea, pneumonia, and cellulitis. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue<br \/>\n      (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%), decreased<br \/>\n      appetite (26%), constipation (21%), arthralgia (20%), and diarrhea (20%).\n    <\/p>\n<p>\n      Among the 550 patients with metastatic NSCLC, KEYTRUDA was discontinued<br \/>\n      due to adverse reactions in 14% of patients. Serious adverse reactions<br \/>\n      occurred in 38% of patients. The most frequent serious adverse reactions<br \/>\n      reported in 2% or more of patients were pleural effusion, pneumonia,<br \/>\n      dyspnea, pulmonary embolism, and pneumonitis. The most common adverse<br \/>\n      reactions (reported in at least 20% of patients) were fatigue (44%),<br \/>\n      decreased appetite (25%), dyspnea (23%), and cough (29%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA<\/b> <b>(pembrolizumab)<br \/>\n      at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=2&amp;md5=e57a329e9d7302f4ab924ffd4587185c\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA<\/b> <b>at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=3&amp;md5=b98da9eab75331d71c800629424d53b2\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<p>\n      <b>GSK<\/b> \u2013 one of the world\u2019s leading research-based pharmaceutical<br \/>\n      and healthcare companies \u2013 is committed to improving the quality of<br \/>\n      human life by enabling people to do more, feel better and live longer.<br \/>\n      For further information please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gsk.com&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=www.gsk.com&amp;index=4&amp;md5=c38ea9d18315c90d892be73a9039c077\" rel=\"nofollow\">www.gsk.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=5&amp;md5=8cca786c70ef123e703cee50f0f192bf\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=6&amp;md5=e0483445983a2436ef3992a78af8291d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIedEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrhdLCXCXCOsVHkiP9C9jDYunNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzztxwgD7GV&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=Twitter&amp;index=7&amp;md5=6c6b80d0d565d5f982edd807920cab96\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIgdEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrjdLCXCXCM0jKSYxmFnBYl-dyF3P7DDCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96Qrzzu-jj&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=61943d644a5180e8380cc64b2bb80703\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2FavndzgA76Qm4m71PwV5ATsSCyOeu7nju76QQmhPMWXba9Jd5AsYeKCYYrhKyqeknbKc8CRvzoHm5GDR8BF_GEacmm8DR8qvOVINpoyvkxF_bCTnbI9LIfZvxOr_nKnjpvuV5AseVqWdAklrFFYG7DR8OJMddICTPtPtPo08JlKrp3-nNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzzqvgF&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=2aa891774624c179f6ab3705d55c304a\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n<p class=\"bwcellpmargin\">\n            <b>GSK enquiries:<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          UK Media enquiries:\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          David Mawdsley\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5502\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Simon Steel\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5502\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          David Daley\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5502\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Catherine Hartley\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5502\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Claire Brough\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5502\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          US Media enquiries:\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Sarah Alspach\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 202 715 1048\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (Washington, DC)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Sarah Spencer\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 215 751 3335\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (Philadelphia)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Mary Anne Rhyne\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 919 483 0492\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (North Carolina)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Jenni Ligday\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 202 715 1049\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (Washington, DC)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Karen Hagens\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 919 483 2863\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (North Carolina)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Gwynne Oosterbaan\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 215 751 7468\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (Philadelphia)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Analyst\/Investor enquiries:\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Ziba Shamsi\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5543\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Tom Curry\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          + 1 215 751 5419\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (Philadelphia)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Gary Davies\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 5503\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          James Dodwell\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +44 (0) 20 8047 2406\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (London)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          Jeff McLaughlin\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          +1 215 751 7002\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          (Philadelphia)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      <b>GSK cautionary statement regarding forward-looking statements<\/b>\n    <\/p>\n<p>\n      GSK cautions investors that any forward-looking statements or<br \/>\n      projections made by GSK, including those made in this announcement, are<br \/>\n      subject to risks and uncertainties that may cause actual results to<br \/>\n      differ materially from those projected. Such factors include, but are<br \/>\n      not limited to, those described under Item 3.D &#8216;Risk factors&#8217; in the<br \/>\n      company&#8217;s Annual Report on Form 20-F for 2014.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51215202&amp;newsitemid=20151103005502&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=fb59205b128bc1753cd2067018511b20\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151103005502r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Relations:<br \/>Pamela Eisele, +1 267-305-3558<br \/>or<br \/>An        Phan, +1 908-255-6325<br \/>or<br \/>Investor Relations:<br \/>Justin        Holko, +1 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase I first-in-human study to evaluate GSK\u2019s OX40 agonist GSK3174998 as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK\u2019s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. GSK3174998 is a humanised IgG1 anti-OX40 monoclonal antibody that was identified through a collaboration with MD Anderson Cancer Center. OX40 is a tumour necrosis factor receptor expressed on the surface of activated CD4+ and CD8+ T cells. OX40 agonism results in stimulation of both immune effector and memory functions, while also attenuating the immunosuppressive regulatory T cells that are sometimes found in tumours. GSK3174998 is<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289,56],"class_list":["post-745083","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Phase I first-in-human study to evaluate GSK\u2019s OX40 agonist GSK3174998 as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK\u2019s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. GSK3174998 is a humanised IgG1 anti-OX40 monoclonal antibody that was identified through a collaboration with MD Anderson Cancer Center. OX40 is a tumour necrosis factor receptor expressed on the surface of activated CD4+ and CD8+ T cells. OX40 agonism results in stimulation of both immune effector and memory functions, while also attenuating the immunosuppressive regulatory T cells that are sometimes found in tumours. GSK3174998 is\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\\\/\",\"name\":\"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-11-03T06:58:00+00:00\",\"dateModified\":\"2025-11-07T06:24:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment - Merck.com","og_description":"Phase I first-in-human study to evaluate GSK\u2019s OX40 agonist GSK3174998 as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK\u2019s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. GSK3174998 is a humanised IgG1 anti-OX40 monoclonal antibody that was identified through a collaboration with MD Anderson Cancer Center. OX40 is a tumour necrosis factor receptor expressed on the surface of activated CD4+ and CD8+ T cells. OX40 agonism results in stimulation of both immune effector and memory functions, while also attenuating the immunosuppressive regulatory T cells that are sometimes found in tumours. GSK3174998 is","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:50+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/","name":"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-11-03T06:58:00+00:00","dateModified":"2025-11-07T06:24:50+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f062cf43-64c7-46f9-88ed-c49aeb834b7c","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/11\/1\/gsk-logo_highres.jpg","size":"60966","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/11\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/GSK-and-Merck-to-Study-Immunotherapy-Combination-as-Potential-Cancer-Treatment-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745083\/revisions"}],"predecessor-version":[{"id":3674579,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745083\/revisions\/3674579"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745083"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}